Novartis AG Common Stock (NVS)
124.21
+2.12 (1.74%)
NYSE · Last Trade: Aug 16th, 2:49 PM EDT
These stocks look like they can weather almost any storm.
Via The Motley Fool · August 15, 2025
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.
Via Chartmill · August 15, 2025
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.
Via Benzinga · August 13, 2025
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concernsstocktwits.com
Via Stocktwits · August 11, 2025
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premiumstocktwits.com
Via Stocktwits · August 6, 2025
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
Via Benzinga · August 12, 2025
Truist, however, kept a ‘Buy’ rating on the shares.
Via Stocktwits · August 11, 2025
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.
Via Stocktwits · August 11, 2025
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.
Via Benzinga · August 11, 2025
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.
Via Benzinga · August 8, 2025
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.
Via The Motley Fool · August 8, 2025
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.
Via Stocktwits · August 6, 2025
The company is focused on treatments for forms of muscular dystrophy.
Via Investor's Business Daily · August 6, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.
Via Benzinga · July 25, 2025
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This expansion reflects a persistent imbalance between what the nation imports and what it exports in goods, services, income,
Via MarketMinute · July 25, 2025
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Via Benzinga · July 25, 2025
NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.
Via Chartmill · July 25, 2025
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.
Via Investor's Business Daily · July 24, 2025